Alkermes plc. (ALKS)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Dec'10Sep'10
REVENUES:
Total revenues

246,220

412,730

255,243

279,872

223,102

315,762

248,720

304,642

225,150

275,370

217,385

218,841

191,778

213,514

180,241

195,165

156,774

163,098

152,653

151,370

161,214

175,161

159,992

153,424

130,212

154,478

139,802

138,631

163,422

135,909

123,978

152,239

130,473

125,643

71,978

61,883

43,975

49,247

EXPENSES:
Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)

47,211

46,482

42,319

46,223

45,361

49,117

39,410

43,417

44,476

38,507

36,054

39,775

40,412

34,957

35,456

33,998

27,711

34,791

33,806

30,418

39,974

46,368

47,335

43,290

38,839

42,892

45,423

45,991

47,991

38,914

41,491

42,070

51,077

42,752

17,530

16,219

12,860

13,911

Research and development

93,279

198,157

107,671

104,435

102,570

108,972

101,265

106,823

108,346

104,490

104,411

99,153

104,835

89,626

99,444

97,006

101,072

93,686

92,558

87,882

70,278

74,433

78,263

67,207

52,140

48,716

45,947

33,462

35,800

31,319

35,088

37,806

45,190

40,493

28,160

28,050

22,503

23,932

Selling, general and administrative

133,372

154,453

148,701

155,075

141,220

141,227

128,777

138,257

118,147

110,896

99,633

108,950

102,099

97,145

91,145

96,121

89,719

87,472

89,497

71,539

63,050

54,804

51,888

50,663

42,550

44,171

39,454

32,933

34,679

29,867

31,428

29,784

34,432

35,469

36,234

31,497

20,521

18,436

Amortization of acquired intangible assets

9,728

10,213

10,173

10,062

9,952

16,458

16,426

16,247

16,069

15,683

15,643

15,472

15,302

15,323

15,323

15,157

15,156

14,206

14,207

14,052

15,220

15,244

15,244

15,089

12,576

12,856

12,856

12,716

10,322

10,549

10,547

10,434

-

11,896

1,817

-

-

-

Restructuring expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

12,300

-

-

-

-

-

-

-

-

-

Impairment of long-lived assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

3,346

-

-

-

-

-

-

-

-

-

Total expenses

283,590

422,664

308,864

315,795

299,103

315,742

285,878

304,744

287,038

269,535

255,741

263,350

262,648

237,051

241,368

242,282

233,658

230,155

230,068

203,891

188,522

190,849

192,730

176,249

146,105

148,635

143,680

125,102

144,438

110,649

118,554

120,094

188,141

130,610

83,741

75,766

55,884

56,279

OPERATING LOSS

-37,370

-9,934

-53,621

-35,923

-76,001

20

-37,158

-102

-61,888

5,835

-38,356

-44,509

-70,870

-23,537

-61,127

-47,117

-76,884

-67,057

-77,415

-52,521

-27,308

-15,688

-32,738

-22,825

-15,893

5,843

-3,878

13,529

18,984

25,260

5,424

32,145

-57,668

-4,967

-11,763

-13,883

-11,909

-7,032

OTHER INCOME (EXPENSE), NET:
Interest income

2,760

3,191

3,509

3,706

3,570

3,292

2,561

1,900

1,485

1,362

1,173

1,171

943

835

912

994

1,011

1,010

865

795

660

592

546

323

511

255

295

161

171

155

216

299

281

350

383

502

650

673

Interest expense

2,857

3,196

3,385

3,520

3,500

3,478

3,346

3,126

5,487

3,192

3,129

2,923

2,764

4,896

3,375

3,323

3,295

3,319

3,325

3,315

3,288

3,333

3,356

3,385

3,356

3,434

3,477

3,468

11,473

4,703

22,648

10,170

-

10,458

7,561

-

-

2,168

Change in the fair value of contingent consideration

6,800

5,000

1,300

-6,500

-22,600

-2,300

4,200

-19,600

-1,900

5,700

13,600

700

1,600

4,800

-1,000

2,200

1,900

-

1,200

1,500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on the Gainesville Transaction

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

26

9,911

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on sale of property, plant and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

36

12,285

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on sale of investment in Acceleron Pharma Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

15,296

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other expense, net

-658

2,382

-1,664

1,851

-1,721

775

-90

-3,517

792

1,081

-9,078

-119

-1,499

-1,515

-752

-467

249

-988

629

585

-211

33

-921

518

-1,850

210

-469

-170

184

-49

723

923

-286

345

336

89

-83

-82

Total other income (expense), net

6,045

7,377

-240

-4,463

-24,251

-1,711

3,325

-24,343

-5,110

4,951

2,566

-1,171

-1,720

-776

-4,215

-596

-135

-5,736

-605

9,476

-2,839

56,468

-3,695

25,037

-4,695

-2,969

-3,651

-3,477

-11,118

-4,597

-21,709

-8,948

-10,097

-9,763

-6,842

591

567

-1,577

LOSS BEFORE INCOME TAXES

-31,325

-2,557

-53,861

-40,386

-100,252

-1,691

-33,833

-24,445

-66,998

10,786

-35,790

-45,680

-72,590

-24,313

-65,342

-47,713

-77,019

-72,793

-78,020

-43,045

-30,147

40,780

-36,433

2,212

-20,588

2,874

-7,529

10,052

7,866

20,663

-16,285

23,197

-67,765

-14,730

-18,605

-13,292

-11,342

-8,609

INCOME TAX PROVISION (BENEFIT)

7,329

2,797

-983

1,604

-3,854

8,022

611

8,204

-4,493

20,575

486

-2,681

-3,709

-3,172

-2,655

-520

404

-3,411

2,995

3,064

510

10,266

3,523

-1,523

3,766

-15,203

233

2,718

4,867

4,405

422

764

-4,408

98

3,650

-54

41

-943

NET LOSS

-38,654

-5,354

-52,878

-41,990

-96,398

-9,713

-34,444

-32,649

-62,505

-9,789

-36,276

-42,999

-68,881

-21,141

-62,687

-47,193

-77,423

-69,382

-81,015

-46,109

-30,657

30,514

-39,956

3,735

-24,354

18,077

-7,762

7,334

2,999

16,258

-16,707

22,433

-63,357

-14,828

-22,255

-13,238

-11,383

-7,666

LOSS PER ORDINARY SHARE:
Basic and diluted (in dollars loss per ordinary share)

-0.24

-0.02

-0.34

-0.27

-0.62

-0.07

-0.22

-0.21

-0.40

-0.06

-0.24

-0.28

-0.45

-0.15

-0.41

-0.31

-0.51

-0.46

-0.54

-0.31

-0.21

-

-0.27

-

-0.17

-

-

-

-

-

-

-

-

-

-

-0.14

-

-

Basic (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.03

-

0.14

-0.06

0.05

0.02

0.12

-0.13

0.17

-

-0.11

-0.22

-

-0.12

-0.08

Diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.02

-

0.13

-0.06

0.05

0.02

0.12

-0.13

0.17

-

-0.11

-0.22

-

-

-

WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING:
Basic and diluted (in shares)

158,095

157,678

157,199

156,991

156,336

155,520

155,328

155,176

154,424

153,880

153,684

153,392

152,704

152,158

151,652

151,301

150,825

150,356

149,512

148,867

148,089

-

145,896

-

143,358

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

144,913

-

137,172

136,106

134,602

133,272

132,097

131,067

130,434

130,015

129,670

102,474

96,649

95,667

95

Diluted (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

154,300

-

155,408

136,106

143,369

139,677

137,497

131,067

134,945

130,015

129,670

102,474

96,649

-

-

COMPREHENSIVE LOSS:
Net loss

-38,654

-5,354

-52,878

-41,990

-96,398

-9,713

-34,444

-32,649

-62,505

-9,789

-36,276

-42,999

-68,881

-21,141

-62,687

-47,193

-77,423

-69,382

-81,015

-46,109

-30,657

30,514

-39,956

3,735

-24,354

18,077

-7,762

7,334

2,999

16,258

-16,707

22,433

-63,357

-14,828

-22,255

-13,238

-11,383

-7,666

Unrealized gain, net of a tax provision of $87 and $229, respectively

317

-178

-24

896

770

386

314

148

-336

-540

83

-133

72

-467

-261

315

935

-1,084

14

-80

489

-269

-154

4,540

-2,531

4,994

8,506

-408

143

134

-

-

259

27

-188

529

-516

453

Unrealized losses on derivative contracts, net of tax of none, none and $(194), respectively

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-33

-244

-

-

-

Reclassification of unrealized gains to realized gains

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

15,296

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gains (losses) on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,531

-

-

-

143

134

-463

-141

259

27

-188

529

-516

453

Unrealized gains on derivative contracts

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

594

-72

-

-33

-244

-

-

-

COMPREHENSIVE LOSS

-38,337

-5,532

-52,902

-41,094

-95,628

-9,327

-34,130

-32,501

-62,841

-10,329

-36,193

-43,132

-68,809

-21,608

-62,948

-46,878

-76,488

-70,466

-81,001

-46,189

-30,168

30,245

-40,110

-7,021

-26,885

23,071

744

6,926

3,142

16,392

-16,576

22,220

-63,148

-14,834

-22,687

-12,709

-11,899

-7,213

Product sales, net
Total revenues

129,726

149,609

138,774

136,635

99,481

132,650

116,035

109,807

91,842

103,941

93,681

88,756

76,456

79,451

69,802

57,519

49,374

42,816

37,903

37,172

31,137

29,684

25,802

21,595

17,079

20,609

19,227

17,379

14,626

15,917

15,192

12,372

11,014

10,597

9,887

9,686

7,729

6,469

Manufacturing and royalty revenues
Total revenues

116,251

107,287

103,783

127,897

108,915

167,422

116,411

128,241

114,601

138,700

122,677

129,252

114,679

133,804

110,250

137,034

106,159

119,310

114,072

113,162

128,744

143,202

132,028

130,366

111,280

132,680

118,571

119,788

146,919

118,274

107,327

138,380

110,685

112,780

54,039

48,940

35,932

42,623

Research and development revenue
Total revenues

200

11,090

12,686

14,340

14,700

15,570

16,274

18,344

18,707

4,729

1,027

833

643

259

189

612

1,241

972

678

1,036

1,333

2,275

2,162

1,463

1,853

1,189

2,004

1,464

1,877

1,718

1,459

1,487

8,774

2,266

8,052

3,257

314

155

License revenue
Total revenues

-

-

-

1,000

-

-

-

48,250

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-